TW580387B - Pharmaceutical combination comprising tipranavir and ritonavir - Google Patents

Pharmaceutical combination comprising tipranavir and ritonavir Download PDF

Info

Publication number
TW580387B
TW580387B TW088119229A TW88119229A TW580387B TW 580387 B TW580387 B TW 580387B TW 088119229 A TW088119229 A TW 088119229A TW 88119229 A TW88119229 A TW 88119229A TW 580387 B TW580387 B TW 580387B
Authority
TW
Taiwan
Prior art keywords
direnavir
treatment
amount
gram
ritunavir
Prior art date
Application number
TW088119229A
Other languages
English (en)
Chinese (zh)
Inventor
James J Ferry
John R Baldwin
Marie T Borin
Original Assignee
Upjohn Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Upjohn Co filed Critical Upjohn Co
Application granted granted Critical
Publication of TW580387B publication Critical patent/TW580387B/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
TW088119229A 1998-11-04 1999-11-04 Pharmaceutical combination comprising tipranavir and ritonavir TW580387B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10696398P 1998-11-04 1998-11-04

Publications (1)

Publication Number Publication Date
TW580387B true TW580387B (en) 2004-03-21

Family

ID=22314155

Family Applications (1)

Application Number Title Priority Date Filing Date
TW088119229A TW580387B (en) 1998-11-04 1999-11-04 Pharmaceutical combination comprising tipranavir and ritonavir

Country Status (13)

Country Link
US (1) US6147095A (enExample)
EP (1) EP1126847A1 (enExample)
JP (1) JP2002528502A (enExample)
CN (1) CN1154491C (enExample)
AU (1) AU762349B2 (enExample)
BR (1) BR9914940A (enExample)
CA (1) CA2346131C (enExample)
CO (1) CO5160321A1 (enExample)
HK (1) HK1040625B (enExample)
MY (1) MY118526A (enExample)
PE (1) PE20001296A1 (enExample)
TW (1) TW580387B (enExample)
WO (1) WO2000025784A1 (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9815567D0 (en) * 1998-07-18 1998-09-16 Glaxo Group Ltd Antiviral compound
ATE381922T1 (de) * 2000-10-31 2008-01-15 Boehringer Ingelheim Pharma Perorale, selbst-emulgierende darreichungsformen von pyranon-proteaseinhibitoren
US6500963B2 (en) 2001-02-22 2002-12-31 Boehringer Ingelheim Pharma Kg Process for preparing optically active dihydropyrones
DE10108470A1 (de) * 2001-02-22 2002-09-05 Boehringer Ingelheim Pharma Verfahren zur Herstellung optisch aktiver Dihydropyrone
US20040197321A1 (en) * 2002-03-19 2004-10-07 Tibor Sipos Composition and method to prevent or reduce diarrhea and steatorrhea in HIV patients
US20030180279A1 (en) * 2002-03-19 2003-09-25 Tibor Sipos Composition and method to prevent or reduce diarrhea and steatorrhea in HIV patients
EP1575595A1 (en) * 2002-12-16 2005-09-21 Boehringer Ingelheim International GmbH Use of a combination containing a non-nucleoside reverse transcriptase inhibitor (nnrti) with an inhibitor of cytochrome p450, such as protease inhibitors
US20050020517A1 (en) * 2002-12-16 2005-01-27 Boehringer Ingelheim Pharmaceuticals, Inc. Treatment of HIV infection through combined administration of tipranavir and capravirine
WO2004087139A1 (en) * 2003-03-27 2004-10-14 Boehringer Ingelheim International Gmbh Antiviral combination of tipranavir and a further antiretroviral compound
AR045841A1 (es) * 2004-09-28 2005-11-16 Richmond Sa Com Ind Y Financie Una composicion farmaceutica solida que comprende al tiazolil metil ester del acido [5s-(5r*, 8r*, 10r*,11r*)] -10- hidroxi-2- metil-5-(1-metiletil)-1-[2-(1-metiletil)-4-tiazolil]-3,6-dioxo-8,11-bis(fenilmetil)-2,4,7,12- tetraazatridecan-13-oico y un procedimiento para prepararla.
CA2583187A1 (en) * 2004-11-08 2006-05-18 Boehringer Ingelheim International Gmbh Method for treating hiv infection through co-administration of tipranavir and etravirine
JP2008520672A (ja) * 2004-11-16 2008-06-19 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング チプラナビルとダルナビルの共投与によるｈｉｖ感染症の治療方法
US20060128733A1 (en) * 2004-11-19 2006-06-15 Boehringer Ingelheim International Gmbh Method for treating HIV infection through co-administration of tipranavir and reverset
US20060122220A1 (en) * 2004-11-19 2006-06-08 Boehringer Ingelheim International Gmbh Method for treating HIV infection through co-administration of tipranavir and UK-427,857
CA2585663A1 (en) * 2004-12-01 2006-06-08 Boehringer Ingelheim International Gmbh Method for treating hiv infection through co-administration of tipranavir and sch-417690
JP2008521898A (ja) * 2004-12-01 2008-06-26 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング チプラナビル及びｇｗ８７３１４０を共に投与することを含むｈｉｖ感染症の治療方法
US20060142344A1 (en) * 2004-12-01 2006-06-29 Boehringer Ingelheim International Gmbh Method for treating HIV infection through co-administration of tipranavir and GW695634
KR101518079B1 (ko) 2007-03-12 2015-05-06 넥타르 테라퓨틱스 올리고머-프로테아제 억제제 컨주게이트
EP2262538B1 (en) * 2008-03-12 2014-12-10 Nektar Therapeutics Oligomer-amino acid conjugate
US20100021505A1 (en) * 2008-07-28 2010-01-28 Tibor Sipos Composition and method to prevent or reduce diarrhea and steatorrhea in HIV patients
US20120108501A1 (en) 2009-06-12 2012-05-03 Nektar Therapeutics Protease Inhibitors
BR112012024522A2 (pt) * 2010-04-02 2017-08-08 Phivco 1 Llc combinação, uso de uma combinação, composição farmacêutica, forma de dosagem única , kit, e, método para tratar um distúrbio
CN104160274A (zh) * 2011-05-30 2014-11-19 奥德特里克公司 通过照护点药物动力学曲线分析进行治疗药物监测和投配的方法与组合物

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5608085A (en) * 1995-02-27 1997-03-04 The University Of Tennessee Research Corporation Synthesis of optically active calanolides A and B and enantiomers and related compounds
US6037157A (en) * 1995-06-29 2000-03-14 Abbott Laboratories Method for improving pharmacokinetics
US5932570A (en) * 1996-11-08 1999-08-03 Dupont Pharmaceuticals Company 1-(3-aminoindazol-5-yl)-3-phenylmethyl-cyclic ureas useful as HIV protease inhibitors
ZA9710071B (en) * 1996-11-21 1998-05-25 Abbott Lab Pharmaceutical composition.

Also Published As

Publication number Publication date
MY118526A (en) 2004-11-30
PE20001296A1 (es) 2000-11-23
US6147095A (en) 2000-11-14
CO5160321A1 (es) 2002-05-30
CN1324237A (zh) 2001-11-28
AU762349B2 (en) 2003-06-26
JP2002528502A (ja) 2002-09-03
EP1126847A1 (en) 2001-08-29
CA2346131C (en) 2013-01-15
HK1040625B (zh) 2005-04-01
AU1440400A (en) 2000-05-22
WO2000025784A1 (en) 2000-05-11
HK1040625A1 (en) 2002-06-21
CN1154491C (zh) 2004-06-23
CA2346131A1 (en) 2000-05-11
BR9914940A (pt) 2001-07-10

Similar Documents

Publication Publication Date Title
TW580387B (en) Pharmaceutical combination comprising tipranavir and ritonavir
Wang et al. An overview of the safety, clinical application and antiviral research of the COVID-19 therapeutics
Sohag et al. Revisiting potential druggable targets against SARS‐CoV‐2 and repurposing therapeutics under preclinical study and clinical trials: A comprehensive review
RU2609512C2 (ru) Производные ингенола для реактивации латентного вируса вич
US20140113923A1 (en) Novel antiviral therapies
JPH11507632A (ja) 併用療法を用いたｈｉｖおよび他のウイルス感染の治療
CN101466392B (zh) 用于预防或治疗hiv感染的药用组合物及其应用
Scarabel et al. Pharmacological strategies to prevent SARS-CoV-2 infection and treat the early phases of COVID-19
US12239629B2 (en) Methods for the prophylaxis and treatment of COVID and COVID-19
Peng et al. Current drugs for HIV-1: from challenges to potential in HIV/AIDS
US5977086A (en) Method of inhibiting human immunodeficiency virus by combined use of hydroxyurea, a nucleoside analog, and a protease inhibitor
CA2793749A1 (fr) Nouveaux schemas d'administration de multitherapies utiles pour le traitement des personnes affectees par le virus de l'immunodeficience humaine (vih)
Toro et al. Topical cidofovir for the treatment of dermatologic conditions: verruca, condyloma, intraepithelial neoplasia, herpes simplex and its potential use in smallpox
RU2290197C2 (ru) Фармацевтическое средство для лечения вич-инфекции, содержащая его композиция и способы его применения
CA2460377A1 (fr) Procede de vaccination therapeutique, peptides mutes de la transcriptase inverse de vih et leur utilisation a des fins de vaccination et en diagnostic
US10588896B2 (en) Agents for the treatment of retroviral infectious diseases
KR102808954B1 (ko) 북극고래 유래 재조합 섬유아세포 성장인자 11을 유효성분으로 포함하는 항바이러스 조성물
US20060281673A1 (en) Novel peptide inhibitor of hiv fusion that disrupts the internal trimeric coiled-coil of gp41
Chen et al. Discovery and development of the human immunodeficiency virus protease inhibitor Saquinavir
US20210378985A1 (en) Method and compound for the treatment of hepatitis c
US20230391837A1 (en) Methods of treating, ameliorating, and/or preventing covid-19 infection and related inflammation
Chaudhary et al. Promising Therapeutic Targets to halt the Global Pandemic of SARS CoV-2
Vanangamudi et al. Current and Promising Multiclass Drug Regimens and Long-Acting Formulation Drugs in HIV Therapy
Sension Initial Therapy for Human Immunodeficiency Virus: Broadening the Options
CN106619591A (zh) 奥昔卡因在制备药物中的用途及药物组合物

Legal Events

Date Code Title Description
MK4A Expiration of patent term of an invention patent